In vitro Antifungal and Antibacterial Activities of a New Antifungal Agent, Liranaftate (M-732).
スポンサーリンク
概要
- 論文の詳細を見る
<I>In vitro</I> antifungal and antibacterial activities of a new thiocarbamate antifungal agent, liranaftate (M-732) previously designated piritetrate were tested using an agar plate dilution method in comparison with tolciclate and bifonazole.<BR>Liranaftate exhibited the most potent antidermatophytic activity, for instance, <I>Trichophyton rubrum</I>: the growth of fresh clinical isolate and stock strains was inhibited at similar levels of MIC values, 0.009 to 0.078μg/m<I>l</I> and 0.004 to 0.078μg/m<I>l</I>, respectively. Liranaftate was also considerably potent against dimorphic fungi, <I>Cryptococcus neoformans</I>, and some other filamentous fungi. Some causative organisms of tinea versicolor were more sensitive to liranaftate than to tolciclate or bifonazole. Most <I>Candida</I> spp. and some bacteria including <I>Nocardia</I> spp. were resistant to liranaftate and tolciclate. It was confirmed that liranaftate was more potent in antifungal activity and had a broader spectrum than the two reference agents.
- 日本医真菌学会の論文
日本医真菌学会 | 論文
- (1→3)-β-D-グルカン測定の問題点と進歩
- 両側の肺空洞病変にアスペルギルス感染を合併し抗真菌薬, ミカファンギンとイトラコナゾールの併用療法が有効であった Wegener 肉芽腫症の一例
- Trichophyton tonsurans 臨床分離株に対する各種抗真菌薬の in vitro 抗真菌活性
- 爪白癬の治療について : 日本医真菌学会標準化委員会提案2007
- Candida 属菌種のアゾール系薬感受性試験における現行の日本医真菌学会法, およびその改変法とNCCLS M27-A2法との相関性に関する検討